{"title":"联合电场、卡博赞替尼和放射治疗对转移性肾细胞癌的抗肿瘤作用增强。","authors":"Jinju Heo, Yunhui Jo, Myonggeun Yoon","doi":"10.1007/s12094-025-03898-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the therapeutic potential of combining cabozantinib, electric fields (EFs; also called Tumor Treating Fields [TTFields]), and radiation in the treatment of metastatic renal cell carcinoma (RCC), focusing on overcoming resistance to conventional monotherapeutic regimens.</p><p><strong>Methods: </strong>Human renal cancer cell lines (A498, Caki-1) were treated with cabozantinib (10 µM) for at least 6 h, TTFields (200 kHz, 0.8 V/cm) for 24 h, and radiation (3 Gy), both individually and in combination. Cellular responses, including proliferation, apoptosis, and metastatic potential, were analyzed by flow cytometry and Transwell assays.</p><p><strong>Results: </strong>The combination of cabozantinib, TTFields, and radiation exhibited synergistic effects, significantly reducing cell proliferation, enhancing apoptosis, and suppressing metastatic capacity compared with individual treatments. Triple therapy resulted in marked inhibition of metastasis-related markers and changes in apoptotic profiles compared with the control group.</p><p><strong>Conclusion: </strong>This multimodal therapy demonstrated superior efficacy in reducing the metastatic potential and prolonging the survival of RCC cells, offering a promising approach to overcoming treatment resistance in patients with metastatic RCC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Enhanced anti-tumor effects of combined electric fields, cabozantinib, and radiation therapy in metastatic renal cell carcinoma.\",\"authors\":\"Jinju Heo, Yunhui Jo, Myonggeun Yoon\",\"doi\":\"10.1007/s12094-025-03898-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to evaluate the therapeutic potential of combining cabozantinib, electric fields (EFs; also called Tumor Treating Fields [TTFields]), and radiation in the treatment of metastatic renal cell carcinoma (RCC), focusing on overcoming resistance to conventional monotherapeutic regimens.</p><p><strong>Methods: </strong>Human renal cancer cell lines (A498, Caki-1) were treated with cabozantinib (10 µM) for at least 6 h, TTFields (200 kHz, 0.8 V/cm) for 24 h, and radiation (3 Gy), both individually and in combination. Cellular responses, including proliferation, apoptosis, and metastatic potential, were analyzed by flow cytometry and Transwell assays.</p><p><strong>Results: </strong>The combination of cabozantinib, TTFields, and radiation exhibited synergistic effects, significantly reducing cell proliferation, enhancing apoptosis, and suppressing metastatic capacity compared with individual treatments. Triple therapy resulted in marked inhibition of metastasis-related markers and changes in apoptotic profiles compared with the control group.</p><p><strong>Conclusion: </strong>This multimodal therapy demonstrated superior efficacy in reducing the metastatic potential and prolonging the survival of RCC cells, offering a promising approach to overcoming treatment resistance in patients with metastatic RCC.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-03898-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03898-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Enhanced anti-tumor effects of combined electric fields, cabozantinib, and radiation therapy in metastatic renal cell carcinoma.
Purpose: This study aimed to evaluate the therapeutic potential of combining cabozantinib, electric fields (EFs; also called Tumor Treating Fields [TTFields]), and radiation in the treatment of metastatic renal cell carcinoma (RCC), focusing on overcoming resistance to conventional monotherapeutic regimens.
Methods: Human renal cancer cell lines (A498, Caki-1) were treated with cabozantinib (10 µM) for at least 6 h, TTFields (200 kHz, 0.8 V/cm) for 24 h, and radiation (3 Gy), both individually and in combination. Cellular responses, including proliferation, apoptosis, and metastatic potential, were analyzed by flow cytometry and Transwell assays.
Results: The combination of cabozantinib, TTFields, and radiation exhibited synergistic effects, significantly reducing cell proliferation, enhancing apoptosis, and suppressing metastatic capacity compared with individual treatments. Triple therapy resulted in marked inhibition of metastasis-related markers and changes in apoptotic profiles compared with the control group.
Conclusion: This multimodal therapy demonstrated superior efficacy in reducing the metastatic potential and prolonging the survival of RCC cells, offering a promising approach to overcoming treatment resistance in patients with metastatic RCC.
期刊介绍：
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
